Venus Remedies Expands Oncology Drug Reach in Ukraine, Eyes Further Growth

19 Mar 2024 , 02:16 PM

Venus Remedies, a pharmaceutical company, has obtained marketing authorizations from Ukraine for three oncology drugs: paclitaxel, oxaliplatin, and irinotecan, expanding its reach in the Asia Commonwealth of Independent States (CIS) region.

Saransh Chaudhary, President of Global Critical Care at Venus Remedies, views these approvals as a significant milestone in the company’s global expansion strategy, aiming to introduce its entire oncology product range in Ukraine gradually.

With over 20 years of presence in the Ukrainian market, Venus Remedies holds 57 product registrations in the country, strengthening its position in the international pharmaceutical market and showcasing its commitment to advancing healthcare solutions.

Aditi K Chaudhary, President of International Business at Venus Remedies, highlights the company’s dedication to improving healthcare for diverse populations through this achievement.

The company’s exports to Ukraine amount to USD 2.20 million, with plans to increase this figure by 20% within the next year by enhancing its product portfolio in the country. Venus Remedies is awaiting approval from Ukraine for ten more marketing authorization applications.

For feedback and suggestions, write to us at [e-mail]